Assy Nimer, Beniashvili Zaza, Djibre Agness, Nasser Gattas, Grosovski Maria, Nseir William
Liver Unit, Ziv Medical Center, Zefat 13100, Israel.
World J Gastroenterol. 2009 Jun 28;15(24):3025-31. doi: 10.3748/wjg.15.3025.
To determine whether new cut-off values for alanine aminotransferase (ALT) and baseline hepatitis B virus (HBV) DNA levels better differentiate HBeAg(-) chronic hepatitis B (CHB) patients from inactive chronic carriers.
Ninety-one patients [32 HBeAg(+) CHB, 19 inactive carriers and 40 HBeAg(-) CHB] were followed up for 2 years and were tested for HBV DNA levels by a PCR-based assay. ALT was tested twice during the last 6 mo using new cut-off values: ULN (upper limit of normal) 30 IU/L for males, 19 IU/L for females. Diagnostic accuracy, sensitivity, specificity, positive and negative predictive values were calculated by discriminant analysis.
When using the revised ALT cut-off values, the lowest optimal HBV DNA level that differentiated HBeAg(-) CHB patients from inactive carriers was 50 000 copies/mL. The diagnostic accuracy of HBV DNA to determine inactive carriers with a cut-off of 50 000 copies/mL was similar to the previously recommended cut-off of 100 000 copies/mL (91%). HBV DNA levels were lower than the cut-off value in 95% of inactive carriers and in 28% of HBeAg(-) CHB patients. With ALT < 30 IU/L in men and < 19 IU/L in women and HBV DNA levels < 100 000 copies/mL, the risk of CHB is 5%. On the other hand, if ALT values were > 30 IU in men and > 19 IU in women and baseline HBV DNA levels were > 100 000 copies/mL, the risk is 86%.
New cut-off values for ALT together with HBV DNA levels proposed by AASLD (American Association for the Study of Liver Diseases) and NIH (National Institute of Health) consensus seem appropriate to characterize inactive carriers.
确定丙氨酸氨基转移酶(ALT)的新临界值和基线乙型肝炎病毒(HBV)DNA水平是否能更好地区分HBeAg阴性慢性乙型肝炎(CHB)患者与非活动性慢性携带者。
对91例患者[32例HBeAg阳性CHB、19例非活动性携带者和40例HBeAg阴性CHB]进行了2年的随访,并通过基于聚合酶链反应的检测方法检测HBV DNA水平。在最后6个月内使用新的临界值对ALT进行了两次检测:男性正常上限(ULN)为30 IU/L,女性为19 IU/L。通过判别分析计算诊断准确性、敏感性、特异性、阳性和阴性预测值。
使用修订后的ALT临界值时,区分HBeAg阴性CHB患者与非活动性携带者的最低最佳HBV DNA水平为50000拷贝/mL。以50000拷贝/mL为临界值确定非活动性携带者时,HBV DNA的诊断准确性与先前推荐的100000拷贝/mL临界值相似(91%)。95%的非活动性携带者和28%的HBeAg阴性CHB患者的HBV DNA水平低于临界值。男性ALT<30 IU/L且女性ALT<19 IU/L以及HBV DNA水平<100000拷贝/mL时,CHB的风险为5%。另一方面,如果男性ALT值>30 IU且女性ALT值>19 IU且基线HBV DNA水平>100000拷贝/mL,则风险为86%。
美国肝病研究学会(AASLD)和美国国立卫生研究院(NIH)共识提出的ALT新临界值以及HBV DNA水平似乎适合用于界定非活动性携带者。